Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) announced better-than-expected revenue in Q4 CY2025, with sales up ...

Incyte experienced an 8.2% sell-off after 2026 guidance appeared to miss consensus by $680M, but this was due to a royalties accounting nuance. Click to read.

Incyte Corp (INCY) reports a 28% increase in Q4 revenue, driven by robust sales and strategic pipeline developments, while navigating competitive market pressures.

Incyte Corporation (NASDAQ:INCY) posted fourth-quarter results on Tuesday that showed a miss on earnings, overshadowing a ...

Q4 2025 Management View William Meury, CEO, stated that "our business exceeded expectations on three levels: total sales, Jakafi sales and our core business sales ex-Jakafi," and emphasized that "we ...

On Tuesday, Incyte Corporation (NASDAQ:INCY) reported fourth-quarter earnings that fell short of analyst expectations, despite posting stronger-than-expected revenue growth. The biopharmaceutical ...

Wall Street anticipates earnings of $1.91 a share on revenue of $1.35 billion for the quarter ended December. That would represent a sequential decline from the company’s strong third-quarter ...

CEO William Meury stated that Incyte delivered a strong quarter with total revenues of $1.37 billion and product sales of $1.15 billion, representing a 20% and 19% increase, respectively, versus the ...

- 24-week data from the Phase 3 STOP-HS clinical trial program of povorcitinib in patients with hidradenitis suppurativa (HS) selected as a late-breaking oral presentation “Our presence at EADV ...

During Thursday's morning session, Incyte shares up by 0.35%, currently priced at $105.04. Considering the current price, Stein's 0 shares have a total value of $0.

In a new SEC filing on January 21, it was revealed that Issa, EVP at Incyte (NASDAQ:INCY), executed a significant exercise of company stock options. What Happened: Issa, EVP at Incyte, exercised stock ...

Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress - 24-week data from the Phase 3 STOP-HS ...